Relmada therapeutics, inc.RLMD.US Overview
US StockHealthcare
(No presentation for RLMD)
RLMD Overall Performance
RLMD AI Analysis & Strategy
RLMD Recent Performance
-0.87%
Relmada therapeutics, inc.
0.81%
Avg of Sector
-1.14%
S&P500
RLMD PowerScanner
RLMD Key Information
RLMD Valuation Metrics
RLMD Earnings Table
RLMD Profile
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.